Oppenheimer Thinks Viking Therapeutics Stock Can Soar to $120. Here's the Math Behind the Ultra-Bullish Call.

Key PointsAnalyst opinions and sales projections for weight loss and type 2 diabetes drug VK2735 vary widely, reflecting both promise and uncertainty.

Read the full Veytics brief

We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.